ArticleThe oncologist2019

A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.

Ghassan K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.